Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MSB Mesabi

Closed 01-13 16:00:00 EST

40.63

+0.54

+1.35%

盘后40.63

+0.000.00%

16:26 EST

High41.99	Low40.09	Vol38.39K
Open40.09	D1 Closing40.09	Amplitude4.74%
Mkt Cap533.07M	Tradable Cap532.66M	Total Shares13.12M
T/O1.58M	T/O Rate0.29%	Tradable Shares13.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MSB","market":"US","secType":"STK","nameCN":"Mesabi","latestPrice":40.63,"timestamp":1768338000000,"preClose":40.09,"halted":0,"volume":38392,"hourTrading":{"tag":"盘后","latestPrice":40.63,"preClose":40.63,"latestTime":"16:26 EST","volume":32,"amount":1306.1809,"timestamp":1768339595745},"delay":0,"floatShares":13109915,"shares":13120010,"eps":1.311705,"marketStatus":"Closed","change":0.54,"latestTime":"01-13 16:00:00 EST","open":40.09,"high":41.99,"low":40.09,"amount":1583235.6484,"amplitude":0.047393,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.311705,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768381200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":40.09,"dividendRate":0.171548,"preHourTrading":{"tag":"盘前","latestPrice":40.45,"preClose":40.09,"latestTime":"09:04 EST","volume":28,"amount":1132.41996,"timestamp":1768313087132},"postHourTrading":{"tag":"盘后","latestPrice":40.63,"preClose":40.63,"latestTime":"16:26 EST","volume":32,"amount":1306.1809,"timestamp":1768339595745},"volumeRatio":0.528649,"impliedVol":0.467,"impliedVolPercentile":0.4861},"requestUrl":"/m/hq/s/MSB/wiki","defaultTab":"wiki","newsList":[{"id":"2602582376","title":"New Crypto Exchange BitGW Offers Secure and Compliant Trading: Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2602582376","media":"utoday","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602582376?lang=en_us&edition=fundamental","pubTime":"2026-01-10 08:07","pubTimestamp":1768003620,"startTime":"0","endTime":"0","summary":"In 2026, employing AI instruments in cryptocurrency exchange businesses becomes a dominant trend. BitGW, a U.S.-licensed centralized crypto trading platform, leverages it to enhance the cryptocurrency","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"utodaynews_highlight","url":"https://u.today/reviews/new-crypto-exchange-bitgw-offers-secure-and-compliant-trading-review","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://u.today/reviews/new-crypto-exchange-bitgw-offers-secure-and-compliant-trading-review","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"utodaynews_highlight","symbols":["BTC","BK4157","BK7016","ETH.USD.HKCC","ADA.AU","BK7105","TON.USD.CC","LINK","ETHU","TON.USD.HKCC","BK4601","ETH","APT.USD.HKCC","BK7067","BK7501","ETH.USD.CC","BK7508","METHmain","BK4006","BTC.USD.HKCC","BK7083","MSB.AU","APT.USD.CC","MSB","BTC.AU","SOL.AU"],"gpt_icon":0},{"id":"2602729863","title":"Mesoblast (ASX:MSB) Valuation Check As Leadership Changes And Debt Refinancing Reset Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2602729863","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602729863?lang=en_us&edition=fundamental","pubTime":"2026-01-09 17:34","pubTimestamp":1767951288,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is back in focus after a cluster of late December and early January announcements, including new board leadership, fresh credit arrangements with an existing director, and sizable shelf registrations in both ordinary shares and ADSs.\nSee our latest analysis for Mesoblast.\nThe recent board reshuffle, fresh credit facility and large shelf registrations appear to have caught the market’s eye, with a 1-day share price return of 4.07% and a 7-day share price return of 10.83%...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-leadership-changes-and-d","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-leadership-changes-and-d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","MSB.AU","DCF","MSB","BK7501","BK4006","BK7067"],"gpt_icon":0},{"id":"2601893174","title":"Malaysian Shares End in Red Bucking Regional Gains; MSB Global's Shares Rally 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601893174","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601893174?lang=en_us&edition=fundamental","pubTime":"2026-01-06 17:51","pubTimestamp":1767693071,"startTime":"0","endTime":"0","summary":"Malaysian stocks dropped slightly on Tuesday, snapping yesterday's gains, and bucking a positive regional trend.The FTSE Bursa Malaysia KLCI shed 7.97 points to end 0.5% lower at 1,672.35. The day range was between 1,667.82 and 1,679.26.In corporate news, shares of MSB Global Group  jumped about 18% in close after its unit MSB Machinery Corporation  signed a joint venture deal with Thai Sin Anant Rubber Factory  to establish a new JV in Thailand.Whereas, shares of Sarawak Consolidated Industries  slid about 3% on Tuesday's close after it signed a development deal to undertake a residential and commercial project in Sarawak, Malaysia, through its unit SCIB Development.Shares of Infoline Tec Group  dropped over 1% on close after its unit Infoline IT Solutions secured a deal from Niaga Sari for a sub-contract worth 9.7 million ringgit on a 30-story serviced apartment project in Terengganu, Malaysia.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MSB","BK4006"],"gpt_icon":0},{"id":"2601865699","title":"MSB Global Unit, Thai Sin Anant Form Auto Parts JV in Thailand; Shares Rally 18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601865699","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601865699?lang=en_us&edition=fundamental","pubTime":"2026-01-06 13:24","pubTimestamp":1767677048,"startTime":"0","endTime":"0","summary":"MSB Global Group  unit MSB Machinery Corporation  signed a joint venture deal with Thai Sin Anant Rubber Factory  to establish a new JV in Thailand, according to a Monday Malaysian bourse filing.Shares of the automotive products manufacturer jumped about 18% in Tuesday's midday trade.The JV will be owned 81% by Thai Sin Anant Rubber Factory , and 19% by MSB Machinery Corporation .The JV will see the sole distributor of \"Gold Series\" automotive parts in Thailand, focusing on suspension components, shock absorbers and related parts, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MSB","BK4006"],"gpt_icon":0},{"id":"2600034377","title":"Press Release: Mesoblast Announces Changes to Board of Directors' Leadership Roles","url":"https://stock-news.laohu8.com/highlight/detail?id=2600034377","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600034377?lang=en_us&edition=fundamental","pubTime":"2026-01-02 07:02","pubTimestamp":1767308520,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 01, 2026  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company.Having presided during the most transformational period for the company with its first U.S. Food & Drug Administration  approval and successful product commercialization, Ms Jane Bell will retire from her role as Chair and will remain on the Board as a non-executive director. The Board has unanimously appointed Mr Philip Facchina to the role of non-executive Chair and Ms Lyn Cobley as Chair of the Audit and Risk Committee. Mr William Burns remains as Mesoblast Vice-Chair and Chair of the Nomination and Remuneration Committee.Mr Facchina joined the Mesoblast board in March 2021 and has over forty years of experience in corporate strategy, finance, and business development","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK7067","BK4150","MSB.AU","MSB","MESO","BK4575","BK4232","MSC","BK4006","BK4022","BK7508","BK7501","BK4139"],"gpt_icon":0},{"id":"2595759386","title":"Press Release: Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line","url":"https://stock-news.laohu8.com/highlight/detail?id=2595759386","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595759386?lang=en_us&edition=fundamental","pubTime":"2025-12-30 07:57","pubTimestamp":1767052620,"startTime":"0","endTime":"0","summary":"Mesoblast has option to draw down up to US$125 million by June 30, 2026. New facility does not encumber any of Mesoblast's material assets or intellectual property. The new credit-line has a fixed interest rate of 8.00% per annum, a substantial reduction from Mesoblast's current debt facilities, with a five-year interest only period. The initial US$75 million drawn is unsecured until the remainder of the NovaQuest debt is repaid, no later than July 8, 2026, after which the entire new facility  will be secured solely with the Temcell royalty.Mesoblast's Ryoncil  for the treatment of steroid-refractory acute graft versus host disease  in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell  therapy. Please see the full Prescribing Information at www.ryo","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4232","BK7508","BK4575","MESO","BK7067","R","BK7501","BK4022","MSC","MSB.AU","BK4150","MSB","BK4006"],"gpt_icon":0},{"id":"2591829670","title":"Aspire Announces Major Australia, EU and US Regulatory Milestones, Marking a New Chapter in Its Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2591829670","media":"prnewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591829670?lang=en_us&edition=fundamental","pubTime":"2025-12-16 12:23","pubTimestamp":1765858980,"startTime":"0","endTime":"0","summary":"SINGAPORE, Dec. 16, 2025 /PRNewswire/ -- Aspire, the Singapore-headquartered fintech, today announced a series of regulatory milestones marking a major step in its global expansion. Over the past year alone, the company has secured eight licenses and registrations, strengthening its footprint across Australia, Europe and the United States and laying the foundation for its next phase of growth in some of the world's most important financial hubs.In Australia, Aspire has been granted a full Australian Financial Services License . This strengthens its presence in Asia Pacific and enables the company to deliver its financial stack to Australian businesses directly. With the new license, Aspire will bring its full financial stack, including multicurrency accounts, payments, cards and spend, to Australian companies that increasingly expect a modern, integrated finance platform.2025 has been a defining year for Aspire, from securing major licenses to deepening its footprint in Asia. The compa","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2752414/Aspire_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2752414/Aspire_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/aspire-announces-major-australia-eu-and-us-regulatory-milestones-marking-a-new-chapter-in-its-global-expansion-302642993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0661504455.SGD","SEC.AU","LU1003077747.HKD","LU0545039389.USD","BK7501","XAO.AU","LU0949170772.SGD","BK4585","BK4208","MSB.AU","LU0553294199.USD","BK7067","CMS","LU0738911758.USD","BK4006","XJO.AU","BK4588","LU2637428348.USD","LU2346227817.USD","MSB","BK7508","BK4156","LU1894683348.USD","XKO.AU","LU1894683264.USD","EMI","LU2500361329.USD"],"gpt_icon":0},{"id":"2590547736","title":"Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD","url":"https://stock-news.laohu8.com/highlight/detail?id=2590547736","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590547736?lang=en_us&edition=fundamental","pubTime":"2025-12-12 07:22","pubTimestamp":1765495320,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  11, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent pe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204384/0/en/Independent-Study-Presented-at-American-Society-of-Hematology-ASH-Annual-Meeting-Concludes-Remestemcel-L-Superior-to-Ruxolitinib-in-Clinical-Outcomes-as-Treatment-for-SR-aGvHD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","MSC","BK4107","ASH","LU2463526074.USD","BK4117","SPN","BK4575","BK4109","MSB","BK4139","MESO","AFG","SR","BK4150","BK4197"],"gpt_icon":0},{"id":"2590541654","title":"Is Mesoblast (ASX:MSB) Using High-Profile Conferences To Recast Its Core Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2590541654","media":"Simply Wall St.","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590541654?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:33","pubTimestamp":1765463582,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently presented at the Piper Sandler 37th Annual Healthcare Conference in New York, led by Founder and CEO Silviu Itescu.\nThe CEO’s direct participation in this high-profile healthcare forum positioned Mesoblast to highlight its scientific direction, clinical priorities, and broader corporate story to an influential audience.\nWe’ll now examine how Mesoblast’s high-profile conference appearance with direct CEO participation may influence the company’s broader investment...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-using-high-profile-conferences-to-recast","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblast-asxmsb-using-high-profile-conferences-to-recast","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK4006","BK7067","MSB","BK7501","MSB.AU"],"gpt_icon":0},{"id":"2590574534","title":"Mesoblast (ASX:MSB) Valuation Check as Investors Eye Piper Sandler Healthcare Conference Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2590574534","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590574534?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:27","pubTimestamp":1765373230,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) steps into the spotlight this week as CEO Silviu Itescu presents at the Piper Sandler 37th Annual Healthcare Conference, and traders are watching for fresh color on strategy and late stage trials.\nSee our latest analysis for Mesoblast.\nThat anticipation has arrived on the back of a strong near term rebound, with a 1 month share price return of 27.03 percent and a 1 year total shareholder return of 65.88 percent, even though the year to date share price return remains...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-investors-eye-piper-sand","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-investors-eye-piper-sand","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4137","XBI","LU0128526141.USD","HCSG","BK7508","BK4211","LABU","BK7501","LU0029874061.USD","MSB.AU","MSB","BK7067","XLV","BK4585","ISBC","BK4581","BK4006","DCF"],"gpt_icon":0},{"id":"2590041013","title":"Matrixport Appoints Dominik Oggenfuss as Chief Executive Officer of Matrixport Asset Management AG","url":"https://stock-news.laohu8.com/highlight/detail?id=2590041013","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590041013?lang=en_us&edition=fundamental","pubTime":"2025-12-10 16:00","pubTimestamp":1765353600,"startTime":"0","endTime":"0","summary":"Seasoned finance leader to drive company's next phase of growth and innovation. ZURICH, Dec. 10, 2025 /PRNewswire/ -- Matrixport Groupis pleased to announce the appointment of Dominik Oggenfuss as Chief Executive Officer of Matrixport Asset Management AG, effective today.\"With our Swiss asset management platform in place, Matrixport Asset Management is entering its next phase focused on scaling an institution-grade business across Europe. Dominik's appointment reflects our priorities in strengthening investment capabilities and building a long-term presence in key European markets.\" said John Ge, CEO of Matrixport Group.\"I am honored to join Matrixport Asset Management AG as CEO and I look forward to working with the talented team. Being part of Matrixport Group, a global digital asset player in Asia, I am convinced we can deliver innovative investment solutions, strengthen client relationships, and expand Matrixport Group's presence in both traditional and digital asset markets in Swi","market":"us","thumbnail":"https://mma.prnewswire.com/media/2529911/Matrixport_2024_2025_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2529911/Matrixport_2024_2025_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/matrixport-appoints-dominik-oggenfuss-as-chief-executive-officer-of-matrixport-asset-management-ag-302637423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK4006","BK7508","AG","BK7067","MSB","MSB.AU","BK4210"],"gpt_icon":0},{"id":"2588020600","title":"Mesoblast Participation at Piper Sandler Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2588020600","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588020600?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:10","pubTimestamp":1764803400,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  03, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/03/3199432/0/en/Mesoblast-Participation-at-Piper-Sandler-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","MSB","MSC","BK4139","MESO","BK4575","BK4150"],"gpt_icon":0},{"id":"2587754974","title":"Mesoblast (ASX:MSB) Is Up 17.3% After Lifting Revenue Guidance and Announcing NIH Trial Collaboration Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2587754974","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587754974?lang=en_us&edition=fundamental","pubTime":"2025-11-29 09:23","pubTimestamp":1764379395,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently released updated revenue guidance, projecting gross revenue of over US$30.0 million from Ryoncil® sales for the quarter ending December 31, 2025, and announced a collaborative pivotal trial with the NIH-funded Blood and Marrow Transplant Clinical Trials Network for Ryoncil® in adults with severe acute graft versus host disease.\nThis combination of higher sales forecasts and expanded clinical research signals an important step as Mesoblast seeks to broaden both its...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-173-after-lifting-revenue-guidance-an","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-173-after-lifting-revenue-guidance-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","MSB.AU"],"gpt_icon":0},{"id":"2586248870","title":"A Look at Mesoblast (ASX:MSB) Valuation as New Ryoncil Sales Forecast and Pivotal Trial Spark Attention","url":"https://stock-news.laohu8.com/highlight/detail?id=2586248870","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586248870?lang=en_us&edition=fundamental","pubTime":"2025-11-27 13:37","pubTimestamp":1764221823,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has caught the market's attention with a new revenue forecast for December 2025, expecting sales of Ryoncil to top $30 million, an increase of 37% from the previous quarter. The company also announced a collaboration to launch a pivotal trial that could expand Ryoncil’s use in adults with severe graft versus host disease.\nSee our latest analysis for Mesoblast.\nMesoblast’s upbeat revenue guidance and new clinical trial plans have reinvigorated investor sentiment, reflected...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblast-asxmsb-valuation-as-new-ryoncil-sales-fo","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblast-asxmsb-valuation-as-new-ryoncil-sales-fo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","MSB.AU"],"gpt_icon":0},{"id":"2585417117","title":"How a Seasoned CFO Appointment Could Shape Mesoblast's (ASX:MSB) Commercial Transformation","url":"https://stock-news.laohu8.com/highlight/detail?id=2585417117","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585417117?lang=en_us&edition=fundamental","pubTime":"2025-11-21 16:18","pubTimestamp":1763713089,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently announced the appointment of James M. O’Brien as its new US-based Chief Financial Officer, drawing on his extensive financial leadership across global life sciences, biotechnology, and pharmaceutical companies.\nO’Brien’s expertise in orchestrating large-scale corporate transactions and public offerings brings significant operational and financial acumen to Mesoblast's transition into a fully integrated commercial organization.\nWe’ll now explore how the addition of...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/how-a-seasoned-cfo-appointment-could-shape-mesoblasts-asxmsb","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/how-a-seasoned-cfo-appointment-could-shape-mesoblasts-asxmsb","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","BK4006","BK7501","BK7508","MSB","BK7067"],"gpt_icon":0},{"id":"2585166564","title":"Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids","url":"https://stock-news.laohu8.com/highlight/detail?id=2585166564","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585166564?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:32","pubTimestamp":1763681520,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov.  20, 2025  (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high ra","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/20/3192470/0/en/Mesoblast-and-BMT-CTN-to-Initiate-Pivotal-Trial-of-Ryoncil-as-Part-of-First-Line-Regimen-in-Adults-with-Severe-Acute-GVHD-Refractory-to-Steroids.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4006","MSB","BK4139","BK4535","BK4192","MESO","BK4150","BK4575","MCW","MSC"],"gpt_icon":0},{"id":"2584464645","title":"iFAST vs SGX: Which Growth Stock Could Deliver Better Returns in 2026?","url":"https://stock-news.laohu8.com/highlight/detail?id=2584464645","media":"The Smart Investor","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584464645?lang=en_us&edition=fundamental","pubTime":"2025-11-17 17:30","pubTimestamp":1763371800,"startTime":"0","endTime":"0","summary":"Which growth stock stands to achieve better returns in 2026?","market":"us","thumbnail":"https://thesmartinvestor.com.sg/wp-content/uploads/2025/11/iFAST-vs-SGX-300x200.png","type":0,"news_type":0,"thumbnails":["https://thesmartinvestor.com.sg/wp-content/uploads/2025/11/iFAST-vs-SGX-300x200.png"],"rights":{"source":"thesmartinvestor_highlight","url":"https://thesmartinvestor.com.sg/ifast-vs-sgx-which-growth-stock-could-deliver-better-returns-in-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://thesmartinvestor.com.sg/ifast-vs-sgx-which-growth-stock-could-deliver-better-returns-in-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"thesmartinvestor_highlight","symbols":["BK6033","LU0532188223.SGD","BK4006","SG9999013486.USD","SGXZ58947870.SGD","LU1920063259.USD","SG9999004360.SGD","LU1119993845.HKD","LU1920062954.HKD","MSB","BK6503","SG9999013460.SGD","LU0326948709.USD","CIX","BK6052","SG9999003826.SGD","SG9999000343.SGD","BK4143","SG9999006266.SGD","LU0192582467.USD","LU1839390173.USD","AIY.SI","LU2242646235.USD","SG9999014484.SGD","LU2242646821.SGD","SG9999014492.USD","SG9999001846.SGD","LU2242652126.USD","BK6523","SGXZ27511609.SGD","LU0205439572.USD","LU0831103253.SGD","SG9999013478.USD","LU0898667661.SGD","LU0877626530.USD","S68.SI","SG9999001135.SGD","LU0441851309.USD","SG9999016042.SGD","LU0188438112.USD","IE00BKZH1Z71.USD","LU2401740654.USD","BK6516"],"gpt_icon":0},{"id":"2584737614","title":"Press Release: James M. O'Brien Appointed Chief Financial Officer at Mesoblast","url":"https://stock-news.laohu8.com/highlight/detail?id=2584737614","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584737614?lang=en_us&edition=fundamental","pubTime":"2025-11-17 14:52","pubTimestamp":1763362320,"startTime":"0","endTime":"0","summary":"NEW YORK, Nov. 17, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company's transition to a fully integrated commercial organization it has appointed James M. O'Brien as its US-based Chief Financial Officer . Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries.Mesoblast  is a world leader in developing allogeneic  cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant red","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK4006","BK7067","BMS","CFO","BK7501","R","BK4232","MSB.AU","MSB","BK4022","BK4575","MESO","BK4139","MSC","BK4150"],"gpt_icon":0},{"id":"2584869657","title":"Mesoblast (ASX:MSB) Valuation Spotlight as FDA Reviews Opioid-Reducing Therapy Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2584869657","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584869657?lang=en_us&edition=fundamental","pubTime":"2025-11-17 00:15","pubTimestamp":1763309724,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) revealed that the US FDA will convene in December to review data from its Phase 3 trial on rexlemestrocel-L. The focus will be on opioid reduction in chronic low back pain patients. This closely follows updated FDA guidance prioritizing non-opioid therapies in response to the ongoing opioid crisis.\nSee our latest analysis for Mesoblast.\nMesoblast shares have seen sharp swings this year, with the latest price at $2.22 and a 30-day share price return of -20.71% reflecting...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-spotlight-as-fda-reviews-opioid-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-spotlight-as-fda-reviews-opioid-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4006","BK7501","DCF","BK7067","BK7508","MSB","MSB.AU"],"gpt_icon":0},{"id":"2582223243","title":"FDA Review of Opioid-Reduction Data Could Be a Game Changer for Mesoblast (ASX:MSB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582223243","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582223243?lang=en_us&edition=fundamental","pubTime":"2025-11-12 17:28","pubTimestamp":1762939694,"startTime":"0","endTime":"0","summary":"Mesoblast Limited recently announced that the U.S. FDA has scheduled a December meeting to review Phase 3 data on opioid reduction and cessation for its investigational therapy rexlemestrocel-L in patients with chronic low back pain (CLBP), following a trial showing higher opioid cessation rates compared to controls.\nThis FDA engagement comes amid new guidance promoting non-opioid pain treatments, highlighting the therapy's potential role in addressing the U.S. opioid crisis.\nWe'll explore...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/fda-review-of-opioid-reduction-data-could-be-a-game-changer","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/fda-review-of-opioid-reduction-data-could-be-a-game-changer","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","MSB.AU","BK7501","MSB","BK7508","BK4006"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mesabi-trust.com","stockEarnings":[{"period":"1week","weight":0.0815},{"period":"1month","weight":0.1577},{"period":"3month","weight":0.24},{"period":"6month","weight":0.5697},{"period":"1year","weight":0.5043},{"period":"ytd","weight":0.0408}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.0497},{"period":"6month","weight":0.1136},{"period":"1year","weight":0.1975},{"period":"ytd","weight":0.0194}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. Mesabi Trust was founded in 1961 and is based in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.586957,"avgChangeRate":0.063955},{"month":2,"riseRate":0.577778,"avgChangeRate":0.033796},{"month":3,"riseRate":0.4,"avgChangeRate":0.011105},{"month":4,"riseRate":0.391304,"avgChangeRate":-0.003842},{"month":5,"riseRate":0.521739,"avgChangeRate":0.010145},{"month":6,"riseRate":0.369565,"avgChangeRate":-0.009375},{"month":7,"riseRate":0.347826,"avgChangeRate":-0.009187},{"month":8,"riseRate":0.413043,"avgChangeRate":0.000339},{"month":9,"riseRate":0.413043,"avgChangeRate":0.003772},{"month":10,"riseRate":0.391304,"avgChangeRate":-0.005844},{"month":11,"riseRate":0.478261,"avgChangeRate":-0.001259},{"month":12,"riseRate":0.434783,"avgChangeRate":0.025908}],"exchange":"NYSE","name":"Mesabi","nameEN":"Mesabi"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mesabi,MSB,Mesabi股票,Mesabi股票老虎,Mesabi股票老虎国际,Mesabi行情,Mesabi股票行情,Mesabi股价,Mesabi股市,Mesabi股票价格,Mesabi股票交易,Mesabi股票购买,Mesabi股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mesabi(MSB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mesabi(MSB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}